Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leiomyoma 1Hodgkin Disease 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1Anemia, Refractory, with Excess of Blasts 1Adenomyosis 1

Interventions

Cyclophosphamide 15fludarabine phosphate 11fludarabine 11Whole-Body Irradiation 11Mycophenolic Acid 11Busulfan 9Melphalan 8Tacrolimus 7Peripheral Blood Stem Cell Transplantation 7Granulocyte Colony-Stimulating Factor 5Cyclosporine 5Azacitidine 5Filgrastim 4venetoclax 3Cord Blood Stem Cell Transplantation 3Biopsy 3thymoglobulin 2decitabine and cedazuridine drug combination 2Vorinostat 2Thiotepa 2Specimen Handling 2Sirolimus 2Rituximab 2Methotrexate 2Injections 2Hematopoietic Stem Cell Transplantation 2Etoposide 2Cytarabine 2Cyclosporins 2Clofarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia, Refractory, with Excess of Blasts × Triamcinolone × 1 year × Clear all
NCT03674411 2026-01-06

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Masonic Cancer Center, University of Minnesota

Phase 2 Active not recruiting
22 enrolled 19 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasmSarcoma

Anemia, Refractory, with Excess of Blasts, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡